Drug Discovery Today

APRIL 19, 2022

To provide publishers, universities and scientific researchers with a tool to check image integrity before submission, Dr. Dror Kolodkin-Gal, founder of Proofig, have launched an automated image integrity detection software. This automated artificial intelligence (AI) tool detects the majority of forms of image duplication and some of the manipulation.

Research 100

Research 100

Drug Patent Watch

APRIL 22, 2022

This chart shows the pharmaceutical companies with the most syrup dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most syrup dosed drugs…. The post Which pharmaceutical companies have the most syrup dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 90

Pharmaceutical Companies Pharmaceuticals Drugs 90

Drug Channels

APRIL 20, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Click here to see the original post and comments from January 2022. For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies.

Biosimilars 84

Biosimilars Pharmacy Drugs Production 84

The Pharma Data

APRIL 20, 2022

Today, the U.S. Food and Drug Administration is warning the public of the risk of false results, inappropriate use and inappropriate interpretation of results with non-invasive prenatal screening (NIPS) tests, also called cell-free DNA tests or non-invasive prenatal tests (NIPT). These tests look for signs of genetic abnormalities in a fetus by testing a sample of blood from the pregnant person.

FDA 52

FDA Laboratories DNA Production 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

The Open Targets Blog

APRIL 19, 2022

The Open Targets Platform integrates data from several sources, making connections between targets and diseases or phenotypes and providing context for these associations. In particular, bibliography is a unique source of information to identify and prioritise targets since the whole corpus of literature represents the accumulated knowledge driving therapeutic discoveries.

Disease 52

Disease Bioinformatics FDA Production 52

Drug Patent Watch

APRIL 18, 2022

This chart shows the companies which have received the most New Patient Population exclusivities in the past five years. New Patient Populations are one of the categories for which the…. The post Pharmaceutical companies with the most ‘New Patient Population’ drugs appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 62

Pharmaceutical Companies Pharmaceuticals Drugs 62

The Pharma Data

APRIL 20, 2022

Cancer cells can disrupt a metabolic pathway that breaks down fats and proteins to boost the levels of a byproduct called methylmalonic acid, thereby driving metastasis, according to research led by scientists at Weill Cornell Medicine. The findings open a new lead for understanding how tumors metastasize, or spread to other tissues, and hints at novel ways to block the spread of cancer by targeting the process.

Research 52

Research Production Regulations Science 52

Antidote

APRIL 19, 2022

ESG, short for “Environmental, Social, and Governance,” is a set of standards for a company’s operations that socially conscious investors use to screen potential investments. This year, Antidote is tackling the environmental piece of ESG head-on.

Government 52

Government 52

Drug Patent Watch

APRIL 22, 2022

Annual Drug Patent Expirations for OXYCONTIN Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from eight suppliers. There are nineteen…. The post New patent for Purdue Pharma drug OXYCONTIN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Channels

APRIL 21, 2022

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Click here to see the original post and comments from October 2021. By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. This chart complements Follow the Dollar: The U.S.

Pharmacy 77

Pharmacy Drugs Pharmaceuticals Hospitals 77

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

The Pharma Data

APRIL 20, 2022

Results of a new multicenter study published in the New England Journal of Medicine found that vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine reduced the risk of COVID-19-associated hospitalizations in children ages 5-11 years by two-thirds during the Omicron period. Among adolescents ages 12-18 years who were vaccinated with a primary series of Pfizer-BioNTech vaccine, protection against COVID-19-associated hospitalization during the Omicron period was lower than

Vaccine 52

Vaccine Hospitals Research Disease 52

Crown Bioscience

APRIL 20, 2022

Drug resistance to cancer therapy is a significant problem facing patients. It has been identified as the major factor limiting greater treatment success.

Drugs 52

Drugs Therapies Treatment 52

Drug Patent Watch

APRIL 22, 2022

Annual Drug Patent Expirations for LEQVIO Leqvio is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are nineteen patents protecting…. The post New patent expiration for Novartis drug LEQVIO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Channels

APRIL 19, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Click here to see the original post and comments from November 2021. An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars.

Biosimilars 77

Biosimilars Production FDA Drugs 77

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

The Pharma Data

APRIL 19, 2022

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies. — Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation. Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland.

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

Drug & Device Law

APRIL 21, 2022

Defendants love and plaintiffs hate Bell Atlantic Corp. v. Twombly , 550 U.S. 544 (2007), and Ashcroft v. Iqbal , 556 U.S. 662 (2009), which together stand for the proposition that to state a claim and avoid dismissal a plaintiff must allege facts that plausibly suggest that the defendant is liable. Today’s case, Poozhikala v. Medtronic Inc. , 2022 WL 1076173 (C.D.

Regulations 59

Regulations FDA International Production 59

Drug Patent Watch

APRIL 22, 2022

Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are two…. The post New patent for Pacira Pharms drug EXPAREL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Channels

APRIL 18, 2022

Informa Connect’s PAP – Patient Assistance & Access Programs. Hybrid Event | June 28-30 in Parsippany, NJ www.informaconnect.com/pap. Exclusive Offer – Be sure to use your exclusive promo code 22DCPAP10 to save 10% off* of your registration. Informa Connect is pleased to announce that PAP – Patient Assistance & Access Programs will return as a hybrid event June 28-30 in Parsippany, NJ and virtually through the ConnectMe platform.

Specialty Pharmacies 55

Specialty Pharmacies Pharmacy Hospitals Drugs 55

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

The Pharma Data

APRIL 19, 2022

Based on pivotal DESTINY-Lung01 results showing AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a 54.9% tumour response rate If approved, Enhertu to provide patients with a much-needed targeted therapy option. AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic non-small cell lung cancer (NSCLC) whose

Trials 52

Trials Treatment Therapies FDA 52

Drug & Device Law

APRIL 22, 2022

The Ninth Circuit has certified a question to the California Supreme Court on the learned intermediary doctrine that immediately caught our attention: In a failure-to-warn claim against a prescription medical product manufacturer, is the plaintiff required to show that a stronger warning would have altered the physician’s decision to prescribe the product?

Doctors 52

Doctors Therapies Treatment Production 52

Drug Patent Watch

APRIL 22, 2022

Annual Drug Patent Expirations for LOREEV+XR Loreev Xr is a drug marketed by Almatica and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Almatica drug LOREEV XR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 22, 2022

Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are…. The post New patent for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 21, 2022

This chart shows the pharmaceutical companies with the most patents in Yugoslavia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Yugoslavia? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

APRIL 21, 2022

Bendamustine hydrochloride is the generic ingredient in three branded drugs marketed by Cephalon and Eagle Pharms and is included in three NDAs. There are twenty-five patents protecting this compound. Drug…. The post New tentative approval for Apotex Inc drug bendamustine hydrochloride appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 21, 2022

Annual Drug Patent Expirations for RINVOQ Rinvoq is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are fourteen patents…. The post New patent for Abbvie Inc drug RINVOQ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 20, 2022

Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 20, 2022

Annual Drug Patent Expirations for TIROSINT-SOL Tirosint-sol is a drug marketed by Institut Biochimique and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Institut Biochimique drug TIROSINT-SOL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 20, 2022

Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are twenty-nine patents protecting this drug. This drug…. The post New patent for Amicus Therap drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 20, 2022

Annual Drug Patent Expirations for HEMADY Hemady is a drug marketed by Dexcel Pharma and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent for Dexcel Pharma drug HEMADY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 19, 2022

This chart shows the pharmaceutical companies with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

APRIL 19, 2022

Annual Drug Patent Expirations for VOCABRIA Vocabria is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Viiv Hlthcare drug VOCABRIA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

APRIL 19, 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia.

Pharmaceutical Companies 52

Pharmaceutical Companies Compliance Biosimilars Pharmaceuticals 52

The Pharma Data

APRIL 19, 2022

Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme, consisting of five trials that all met their primary efficacy and safety endpoints in non-dialysis and dialysis patients US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat following the European Medicines Agency (EMA) regulatory submission acceptance and approval of Duvroq in Japan.

Clinical Trials 52

Clinical Trials Drugs Trials FDA 52